---
title: "Basel Medical Group Ltd (BMGL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BMGL.US.md"
symbol: "BMGL.US"
name: "Basel Medical Group Ltd"
industry: "Health Care Services"
datetime: "2026-06-13T16:25:51.916Z"
locales:
  - [en](https://longbridge.com/en/quote/BMGL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BMGL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BMGL.US.md)
---

# Basel Medical Group Ltd (BMGL.US)

## Company Overview

Basel Medical Group Ltd provides healthcare services in Singapore. The company offers general and subspecialized orthopedic, including trauma and sports medicine services, such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, and minimally invasive orthopedic procedures, as well as neurosurgical treatments. It also provides health screening services, mental health, woman’s health, and general practice services. In addition, its services include consultation, medical diagnosis, and medical and surgical treatments.

| Item | Detail |
|------|--------|
| Industry | Health Care Services |
| Exchange | US Market |
| Website | [baselmedical.com](https://baselmedical.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:12.000Z

**Overall: C (0.58)**

**Industry**: Health Care Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 55 / 86 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.86% |  |
| Net Profit YoY | -626.21% |  |
| P/B Ratio | 2.60 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 11081713.93 |  |
| Revenue | 8646877.13 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -163.67% | E |
| Profit Margin | -93.67% | E |
| Gross Margin | 21.18% | D |
| Revenue YoY | 15.86% | B |
| Net Profit YoY | -626.21% | E |
| Total Assets YoY | 21.68% | A |
| Net Assets YoY | -23.60% | E |
| Cash Flow Margin | 38.02% | D |
| OCF YoY | 15.86% | B |
| Turnover | 0.65 | B |
| Gearing Ratio | 70.89% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Basel Medical Group Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.86%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-626.21%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.60",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "11081713.93",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8646877.13",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-163.67%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-93.67%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "21.18%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "15.86%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-626.21%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "21.68%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-23.60%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "38.02%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "15.86%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.65",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "70.89%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.37 | 39/86 | 123.47 | 111.77 | 91.87 |
| PB | 2.60 | 26/86 | 6.90 | 4.09 | 2.81 |
| PS (TTM) | 1.28 | 31/86 | 4.91 | 1.69 | 1.28 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cigna (CI.US) | B | C | A | D | B | B |
| 02 | BrightSpring Health Services - Unit (BTSGU.US) | C | A | A | D | B | B |
| 03 | Fresenius (FSNUY.US) | C | B | C | C | B | B |
| 04 | Quest Diagnostics (DGX.US) | B | B | B | C | B | B |
| 05 | Labcorp (LH.US) | B | B | B | C | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BMGL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BMGL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BMGL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BMGL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**